Completed PHASE3 INTERVENTIONAL 6-arm NCT00433836

Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure

A Multicenter, Randomized, Double-blind, Parallel-group, Evaluation of 12 Weeks of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children 6 to 17 Years of Age With Hypertension

Sponsor: Novartis Pharmaceuticals

Conditions Hypertension

Interventions Enalapril Valsartan

Updated 7 times since 2017 Last updated: Apr 19, 2011 Started: Jan 31, 2007 Primary completion: Feb 28, 2009 Completion: Feb 28, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hypertension and is currently completed. Novartis Pharmaceuticals leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

East Hanover, United States , Hungary, Hungary , Poland, Poland , Sites in Belgium, Belgium , Sites in France, France , Sites in Germany, Germany , Sites in India, India , Sites in Italy, Italy , Sites in Sweden, Sweden , Slovakia, Slovakia and 1 more location